MIND Technology reported a Q2 fiscal 2027 revenue of $5.6 million, down from $9.7 million in Q1 and $13.6 million a year ago, resulting in a $1.7 million net loss. The decline reflects ongoing market softness and uncertain order timing, although after-market sales contributed 87% of revenue, providing stability. The company remains debt-free with $15.8 million in cash and is focused on strategic investments and share repurchases to strengthen its position. Management is cautiously optimistic about long-term demand in marine exploration despite near-term challenges.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Casey's General Stores reported strong Q1 2026 results, surpassing analyst expectations with an EPS of $7.37 versus $6.78 estimated and revenue of $5.68 billion beating the $5.56 billion forecast. Net income rose 27.1% year-over-year to $273.7 millio...
Academy Sports and Outdoors will announce its Q2 2026 earnings on September 9, with revenue expected to rise 3.8% year-over-year to about $1.66 billion. Analysts forecast earnings per share between $2.07 and $2.12, up from $1.94 last year, indicating...
Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive tria...
